Ginkgo Bioworks Stock: Bull vs. Bear
Once upon a time, Ginkgo Bioworks (NYSE: DNA) was viewed by many as a rising star in the biotechnology world. However, since its initial public offering in September 2021, the stock has plunged 95%. So far in 2024, Ginkgo's shares have fallen more than 60%.
Can Ginkgo Bioworks stage a major comeback? Or is the stock likely to continue floundering? Two Motley Fool contributors make the bull and bear arguments for Ginkgo.
Adria Cimino: Ginkgo Bioworks has built a cell engineering platform that's attracted a wide range of customers across industries. The company has seen the most growth, though, in the healthcare and food and agriculture businesses. In pharma and biotech, Ginkgo's number of active programs increased 20% in the first quarter from the year-earlier period. And in food and agriculture, the number climbed more than 50%.
Source Fool.com
